Global Radiopharmaceutical for Nuclear Medicine Market Growth (Status and Outlook) 2026-2032
The global Radiopharmaceutical for Nuclear Medicine market size is predicted to grow from US$ 10613 million in 2025 to US$ 19629 million in 2032; it is expected to grow at a CAGR of 9.1% from 2026 to 2032.
Radiopharmaceuticals for nuclear medicine are a class of specialized drugs that combine radioactive isotopes with biologically active molecules for in vivo diagnosis and therapy. Their primary functions include imaging organs or lesions using radioactive tracers and delivering targeted radiation to tumors or diseased tissues. These drugs encompass single-photon emission computed tomography (SPECT) tracers, positron emission tomography (PET) tracers, and therapeutic radiopharmaceuticals, widely applied in oncology, cardiovascular and cerebrovascular diseases, neurological disorders, and bone diseases. The key advantages of radiopharmaceuticals lie in their high sensitivity, quantifiability, non-invasiveness, and the ability to detect diseases at early stages while enabling individualized treatment planning. With advances in nuclear imaging and radiopharmaceutical production technologies, their role in precision medicine and personalized therapy is increasingly significant.The average gross profit margin of this product is 72%.
The rapidly growing demand for precision diagnostics and personalized therapy provides significant growth opportunities for the radiopharmaceutical market. The high prevalence of cancer and cardiovascular diseases continues to drive demand for both diagnostic and therapeutic applications. The adoption of advanced imaging technologies such as PET/CT and SPECT/CT has enhanced the clinical value of radiopharmaceuticals. Meanwhile, advancements in molecularly targeted and therapeutic radiopharmaceuticals are expanding clinical indications. Government support for early disease screening and precision medicine, combined with improvements in healthcare infrastructure, further fuels market growth. The production and use of radiopharmaceuticals involve highly radioactive materials, imposing strict safety, transportation, and regulatory compliance requirements. The short half-life of radioactive isotopes creates supply chain constraints, impacting product stability and availability. Long development cycles, high investment, and technical complexity limit rapid innovation. Additionally, stringent regulatory approval processes and reimbursement policies may restrict market access and pricing, while specialized clinical expertise requirements constrain adoption. Clinical demand is shifting toward high-sensitivity, low-dose, and personalized radiopharmaceuticals, requiring more precise imaging and therapeutic planning. The integration of diagnostic and therapeutic approaches is driving growth in therapeutic radiopharmaceutical demand. Expansion into primary care and specialized centers also increases demand for small-dose, rapidly prepared, and user-friendly products. The growing emphasis on individualized precision medicine has elevated the importance of multimodal imaging and targeted therapy, generating diversified market needs. Upstream materials for radiopharmaceuticals primarily include radioactive isotopes, chemical precursors, and labeling or synthesis reagents. Radioactive isotopes are the core material, with supply constrained by reactor or accelerator capacity and isotope half-life. Chemical precursors and labeling reagents directly determine drug purity, stability, and biocompatibility. High-purity and controlled processes are critical, as any material variability can impact clinical safety and efficacy. With advancements in domestic isotope production and synthesis technologies, upstream supply is gradually being localized, though stringent quality standards and process consistency remain essential.
LPI (LP Information)' newest research report, the ?Radiopharmaceutical for Nuclear Medicine Industry Forecast? looks at past sales and reviews total world Radiopharmaceutical for Nuclear Medicine sales in 2025, providing a comprehensive analysis by region and market sector of projected Radiopharmaceutical for Nuclear Medicine sales for 2026 through 2032. With Radiopharmaceutical for Nuclear Medicine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Radiopharmaceutical for Nuclear Medicine industry.
This Insight Report provides a comprehensive analysis of the global Radiopharmaceutical for Nuclear Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Radiopharmaceutical for Nuclear Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Radiopharmaceutical for Nuclear Medicine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Radiopharmaceutical for Nuclear Medicine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Radiopharmaceutical for Nuclear Medicine.
This report presents a comprehensive overview, market shares, and growth opportunities of Radiopharmaceutical for Nuclear Medicine market by product type, application, key players and key regions and countries.
Segmentation by Type:
Radiopharmaceuticals for nuclear medicine are a class of specialized drugs that combine radioactive isotopes with biologically active molecules for in vivo diagnosis and therapy. Their primary functions include imaging organs or lesions using radioactive tracers and delivering targeted radiation to tumors or diseased tissues. These drugs encompass single-photon emission computed tomography (SPECT) tracers, positron emission tomography (PET) tracers, and therapeutic radiopharmaceuticals, widely applied in oncology, cardiovascular and cerebrovascular diseases, neurological disorders, and bone diseases. The key advantages of radiopharmaceuticals lie in their high sensitivity, quantifiability, non-invasiveness, and the ability to detect diseases at early stages while enabling individualized treatment planning. With advances in nuclear imaging and radiopharmaceutical production technologies, their role in precision medicine and personalized therapy is increasingly significant.The average gross profit margin of this product is 72%.
The rapidly growing demand for precision diagnostics and personalized therapy provides significant growth opportunities for the radiopharmaceutical market. The high prevalence of cancer and cardiovascular diseases continues to drive demand for both diagnostic and therapeutic applications. The adoption of advanced imaging technologies such as PET/CT and SPECT/CT has enhanced the clinical value of radiopharmaceuticals. Meanwhile, advancements in molecularly targeted and therapeutic radiopharmaceuticals are expanding clinical indications. Government support for early disease screening and precision medicine, combined with improvements in healthcare infrastructure, further fuels market growth. The production and use of radiopharmaceuticals involve highly radioactive materials, imposing strict safety, transportation, and regulatory compliance requirements. The short half-life of radioactive isotopes creates supply chain constraints, impacting product stability and availability. Long development cycles, high investment, and technical complexity limit rapid innovation. Additionally, stringent regulatory approval processes and reimbursement policies may restrict market access and pricing, while specialized clinical expertise requirements constrain adoption. Clinical demand is shifting toward high-sensitivity, low-dose, and personalized radiopharmaceuticals, requiring more precise imaging and therapeutic planning. The integration of diagnostic and therapeutic approaches is driving growth in therapeutic radiopharmaceutical demand. Expansion into primary care and specialized centers also increases demand for small-dose, rapidly prepared, and user-friendly products. The growing emphasis on individualized precision medicine has elevated the importance of multimodal imaging and targeted therapy, generating diversified market needs. Upstream materials for radiopharmaceuticals primarily include radioactive isotopes, chemical precursors, and labeling or synthesis reagents. Radioactive isotopes are the core material, with supply constrained by reactor or accelerator capacity and isotope half-life. Chemical precursors and labeling reagents directly determine drug purity, stability, and biocompatibility. High-purity and controlled processes are critical, as any material variability can impact clinical safety and efficacy. With advancements in domestic isotope production and synthesis technologies, upstream supply is gradually being localized, though stringent quality standards and process consistency remain essential.
LPI (LP Information)' newest research report, the ?Radiopharmaceutical for Nuclear Medicine Industry Forecast? looks at past sales and reviews total world Radiopharmaceutical for Nuclear Medicine sales in 2025, providing a comprehensive analysis by region and market sector of projected Radiopharmaceutical for Nuclear Medicine sales for 2026 through 2032. With Radiopharmaceutical for Nuclear Medicine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Radiopharmaceutical for Nuclear Medicine industry.
This Insight Report provides a comprehensive analysis of the global Radiopharmaceutical for Nuclear Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Radiopharmaceutical for Nuclear Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Radiopharmaceutical for Nuclear Medicine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Radiopharmaceutical for Nuclear Medicine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Radiopharmaceutical for Nuclear Medicine.
This report presents a comprehensive overview, market shares, and growth opportunities of Radiopharmaceutical for Nuclear Medicine market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Diagnosis Nuclear Medicine
- Therapeutic Nuclear Medicine
- Technetium-99m
- Fluorine-18
- Iodine-123
- Iodine-131
- Lutetium-177
- Other
- Hospital
- Imaging Center
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Cardinal Health
- GE Healthcare
- Lantheus Medical Imaging
- Bayer
- Eli Lilly
- Bracco Imaging
- Curium Pharma
- Jubilant Pharmova
- Aurobindo Pharma
- Novartis
- Siemens
- NTP Radioisotopes
- ANSTO
- Polatom
- China Isotope & Radiation
- Yantai Dongcheng
- Seed Biological Pharmacy
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Radiopharmaceutical for Nuclear Medicine Market Size (2021-2032)
2.1.2 Radiopharmaceutical for Nuclear Medicine Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Radiopharmaceutical for Nuclear Medicine by Country/Region (2021, 2025 & 2032)
2.2 Radiopharmaceutical for Nuclear Medicine Segment by Type
2.2.1 Diagnosis Nuclear Medicine
2.2.2 Therapeutic Nuclear Medicine
2.2.3 Radiopharmaceutical for Nuclear Medicine Market Size by Type
2.2.3.1 Radiopharmaceutical for Nuclear Medicine Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Type (2021-2026)
2.3 Radiopharmaceutical for Nuclear Medicine Segment by Disease
2.3.1 Technetium-99m
2.3.2 Fluorine-18
2.3.3 Iodine-123
2.3.4 Iodine-131
2.3.5 Lutetium-177
2.3.6 Other
2.3.7 Radiopharmaceutical for Nuclear Medicine Market Size by Disease
2.3.7.1 Radiopharmaceutical for Nuclear Medicine Market Size CAGR by Disease (2021 VS 2025 VS 2032)
2.3.7.2 Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Disease (2021-2026)
2.4 Radiopharmaceutical for Nuclear Medicine Segment by Application
2.4.1 Hospital
2.4.2 Imaging Center
2.4.3 Others
2.4.4 Radiopharmaceutical for Nuclear Medicine Market Size by Application
2.4.4.1 Radiopharmaceutical for Nuclear Medicine Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.4.4.2 Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Application (2021-2026)
3 RADIOPHARMACEUTICAL FOR NUCLEAR MEDICINE MARKET SIZE BY PLAYER
3.1 Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Player
3.1.1 Global Radiopharmaceutical for Nuclear Medicine Revenue by Player (2021-2026)
3.1.2 Global Radiopharmaceutical for Nuclear Medicine Revenue Market Share by Player (2021-2026)
3.2 Global Radiopharmaceutical for Nuclear Medicine Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 RADIOPHARMACEUTICAL FOR NUCLEAR MEDICINE BY REGION
4.1 Radiopharmaceutical for Nuclear Medicine Market Size by Region (2021-2026)
4.2 Global Radiopharmaceutical for Nuclear Medicine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Radiopharmaceutical for Nuclear Medicine Market Size Growth (2021-2026)
4.4 APAC Radiopharmaceutical for Nuclear Medicine Market Size Growth (2021-2026)
4.5 Europe Radiopharmaceutical for Nuclear Medicine Market Size Growth (2021-2026)
4.6 Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Radiopharmaceutical for Nuclear Medicine Market Size by Country (2021-2026)
5.2 Americas Radiopharmaceutical for Nuclear Medicine Market Size by Type (2021-2026)
5.3 Americas Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Radiopharmaceutical for Nuclear Medicine Market Size by Region (2021-2026)
6.2 APAC Radiopharmaceutical for Nuclear Medicine Market Size by Type (2021-2026)
6.3 APAC Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Radiopharmaceutical for Nuclear Medicine Market Size by Country (2021-2026)
7.2 Europe Radiopharmaceutical for Nuclear Medicine Market Size by Type (2021-2026)
7.3 Europe Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Radiopharmaceutical for Nuclear Medicine by Region (2021-2026)
8.2 Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size by Type (2021-2026)
8.3 Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL RADIOPHARMACEUTICAL FOR NUCLEAR MEDICINE MARKET FORECAST
10.1 Global Radiopharmaceutical for Nuclear Medicine Forecast by Region (2027-2032)
10.1.1 Global Radiopharmaceutical for Nuclear Medicine Forecast by Region (2027-2032)
10.1.2 Americas Radiopharmaceutical for Nuclear Medicine Forecast
10.1.3 APAC Radiopharmaceutical for Nuclear Medicine Forecast
10.1.4 Europe Radiopharmaceutical for Nuclear Medicine Forecast
10.1.5 Middle East & Africa Radiopharmaceutical for Nuclear Medicine Forecast
10.2 Americas Radiopharmaceutical for Nuclear Medicine Forecast by Country (2027-2032)
10.2.1 United States Market Radiopharmaceutical for Nuclear Medicine Forecast
10.2.2 Canada Market Radiopharmaceutical for Nuclear Medicine Forecast
10.2.3 Mexico Market Radiopharmaceutical for Nuclear Medicine Forecast
10.2.4 Brazil Market Radiopharmaceutical for Nuclear Medicine Forecast
10.3 APAC Radiopharmaceutical for Nuclear Medicine Forecast by Region (2027-2032)
10.3.1 China Radiopharmaceutical for Nuclear Medicine Market Forecast
10.3.2 Japan Market Radiopharmaceutical for Nuclear Medicine Forecast
10.3.3 Korea Market Radiopharmaceutical for Nuclear Medicine Forecast
10.3.4 Southeast Asia Market Radiopharmaceutical for Nuclear Medicine Forecast
10.3.5 India Market Radiopharmaceutical for Nuclear Medicine Forecast
10.3.6 Australia Market Radiopharmaceutical for Nuclear Medicine Forecast
10.4 Europe Radiopharmaceutical for Nuclear Medicine Forecast by Country (2027-2032)
10.4.1 Germany Market Radiopharmaceutical for Nuclear Medicine Forecast
10.4.2 France Market Radiopharmaceutical for Nuclear Medicine Forecast
10.4.3 UK Market Radiopharmaceutical for Nuclear Medicine Forecast
10.4.4 Italy Market Radiopharmaceutical for Nuclear Medicine Forecast
10.4.5 Russia Market Radiopharmaceutical for Nuclear Medicine Forecast
10.5 Middle East & Africa Radiopharmaceutical for Nuclear Medicine Forecast by Region (2027-2032)
10.5.1 Egypt Market Radiopharmaceutical for Nuclear Medicine Forecast
10.5.2 South Africa Market Radiopharmaceutical for Nuclear Medicine Forecast
10.5.3 Israel Market Radiopharmaceutical for Nuclear Medicine Forecast
10.5.4 Turkey Market Radiopharmaceutical for Nuclear Medicine Forecast
10.6 Global Radiopharmaceutical for Nuclear Medicine Forecast by Type (2027-2032)
10.7 Global Radiopharmaceutical for Nuclear Medicine Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Radiopharmaceutical for Nuclear Medicine Forecast
11 KEY PLAYERS ANALYSIS
11.1 Cardinal Health
11.1.1 Cardinal Health Company Information
11.1.2 Cardinal Health Radiopharmaceutical for Nuclear Medicine Product Offered
11.1.3 Cardinal Health Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Cardinal Health Main Business Overview
11.1.5 Cardinal Health Latest Developments
11.2 GE Healthcare
11.2.1 GE Healthcare Company Information
11.2.2 GE Healthcare Radiopharmaceutical for Nuclear Medicine Product Offered
11.2.3 GE Healthcare Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 GE Healthcare Main Business Overview
11.2.5 GE Healthcare Latest Developments
11.3 Lantheus Medical Imaging
11.3.1 Lantheus Medical Imaging Company Information
11.3.2 Lantheus Medical Imaging Radiopharmaceutical for Nuclear Medicine Product Offered
11.3.3 Lantheus Medical Imaging Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Lantheus Medical Imaging Main Business Overview
11.3.5 Lantheus Medical Imaging Latest Developments
11.4 Bayer
11.4.1 Bayer Company Information
11.4.2 Bayer Radiopharmaceutical for Nuclear Medicine Product Offered
11.4.3 Bayer Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Bayer Main Business Overview
11.4.5 Bayer Latest Developments
11.5 Eli Lilly
11.5.1 Eli Lilly Company Information
11.5.2 Eli Lilly Radiopharmaceutical for Nuclear Medicine Product Offered
11.5.3 Eli Lilly Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Eli Lilly Main Business Overview
11.5.5 Eli Lilly Latest Developments
11.6 Bracco Imaging
11.6.1 Bracco Imaging Company Information
11.6.2 Bracco Imaging Radiopharmaceutical for Nuclear Medicine Product Offered
11.6.3 Bracco Imaging Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Bracco Imaging Main Business Overview
11.6.5 Bracco Imaging Latest Developments
11.7 Curium Pharma
11.7.1 Curium Pharma Company Information
11.7.2 Curium Pharma Radiopharmaceutical for Nuclear Medicine Product Offered
11.7.3 Curium Pharma Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Curium Pharma Main Business Overview
11.7.5 Curium Pharma Latest Developments
11.8 Jubilant Pharmova
11.8.1 Jubilant Pharmova Company Information
11.8.2 Jubilant Pharmova Radiopharmaceutical for Nuclear Medicine Product Offered
11.8.3 Jubilant Pharmova Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Jubilant Pharmova Main Business Overview
11.8.5 Jubilant Pharmova Latest Developments
11.9 Aurobindo Pharma
11.9.1 Aurobindo Pharma Company Information
11.9.2 Aurobindo Pharma Radiopharmaceutical for Nuclear Medicine Product Offered
11.9.3 Aurobindo Pharma Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Aurobindo Pharma Main Business Overview
11.9.5 Aurobindo Pharma Latest Developments
11.10 Novartis
11.10.1 Novartis Company Information
11.10.2 Novartis Radiopharmaceutical for Nuclear Medicine Product Offered
11.10.3 Novartis Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Novartis Main Business Overview
11.10.5 Novartis Latest Developments
11.11 Siemens
11.11.1 Siemens Company Information
11.11.2 Siemens Radiopharmaceutical for Nuclear Medicine Product Offered
11.11.3 Siemens Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Siemens Main Business Overview
11.11.5 Siemens Latest Developments
11.12 NTP Radioisotopes
11.12.1 NTP Radioisotopes Company Information
11.12.2 NTP Radioisotopes Radiopharmaceutical for Nuclear Medicine Product Offered
11.12.3 NTP Radioisotopes Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 NTP Radioisotopes Main Business Overview
11.12.5 NTP Radioisotopes Latest Developments
11.13 ANSTO
11.13.1 ANSTO Company Information
11.13.2 ANSTO Radiopharmaceutical for Nuclear Medicine Product Offered
11.13.3 ANSTO Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 ANSTO Main Business Overview
11.13.5 ANSTO Latest Developments
11.14 Polatom
11.14.1 Polatom Company Information
11.14.2 Polatom Radiopharmaceutical for Nuclear Medicine Product Offered
11.14.3 Polatom Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Polatom Main Business Overview
11.14.5 Polatom Latest Developments
11.15 China Isotope & Radiation
11.15.1 China Isotope & Radiation Company Information
11.15.2 China Isotope & Radiation Radiopharmaceutical for Nuclear Medicine Product Offered
11.15.3 China Isotope & Radiation Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 China Isotope & Radiation Main Business Overview
11.15.5 China Isotope & Radiation Latest Developments
11.16 Yantai Dongcheng
11.16.1 Yantai Dongcheng Company Information
11.16.2 Yantai Dongcheng Radiopharmaceutical for Nuclear Medicine Product Offered
11.16.3 Yantai Dongcheng Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Yantai Dongcheng Main Business Overview
11.16.5 Yantai Dongcheng Latest Developments
11.17 Seed Biological Pharmacy
11.17.1 Seed Biological Pharmacy Company Information
11.17.2 Seed Biological Pharmacy Radiopharmaceutical for Nuclear Medicine Product Offered
11.17.3 Seed Biological Pharmacy Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Seed Biological Pharmacy Main Business Overview
11.17.5 Seed Biological Pharmacy Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Radiopharmaceutical for Nuclear Medicine Market Size (2021-2032)
2.1.2 Radiopharmaceutical for Nuclear Medicine Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Radiopharmaceutical for Nuclear Medicine by Country/Region (2021, 2025 & 2032)
2.2 Radiopharmaceutical for Nuclear Medicine Segment by Type
2.2.1 Diagnosis Nuclear Medicine
2.2.2 Therapeutic Nuclear Medicine
2.2.3 Radiopharmaceutical for Nuclear Medicine Market Size by Type
2.2.3.1 Radiopharmaceutical for Nuclear Medicine Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Type (2021-2026)
2.3 Radiopharmaceutical for Nuclear Medicine Segment by Disease
2.3.1 Technetium-99m
2.3.2 Fluorine-18
2.3.3 Iodine-123
2.3.4 Iodine-131
2.3.5 Lutetium-177
2.3.6 Other
2.3.7 Radiopharmaceutical for Nuclear Medicine Market Size by Disease
2.3.7.1 Radiopharmaceutical for Nuclear Medicine Market Size CAGR by Disease (2021 VS 2025 VS 2032)
2.3.7.2 Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Disease (2021-2026)
2.4 Radiopharmaceutical for Nuclear Medicine Segment by Application
2.4.1 Hospital
2.4.2 Imaging Center
2.4.3 Others
2.4.4 Radiopharmaceutical for Nuclear Medicine Market Size by Application
2.4.4.1 Radiopharmaceutical for Nuclear Medicine Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.4.4.2 Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Application (2021-2026)
3 RADIOPHARMACEUTICAL FOR NUCLEAR MEDICINE MARKET SIZE BY PLAYER
3.1 Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Player
3.1.1 Global Radiopharmaceutical for Nuclear Medicine Revenue by Player (2021-2026)
3.1.2 Global Radiopharmaceutical for Nuclear Medicine Revenue Market Share by Player (2021-2026)
3.2 Global Radiopharmaceutical for Nuclear Medicine Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 RADIOPHARMACEUTICAL FOR NUCLEAR MEDICINE BY REGION
4.1 Radiopharmaceutical for Nuclear Medicine Market Size by Region (2021-2026)
4.2 Global Radiopharmaceutical for Nuclear Medicine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Radiopharmaceutical for Nuclear Medicine Market Size Growth (2021-2026)
4.4 APAC Radiopharmaceutical for Nuclear Medicine Market Size Growth (2021-2026)
4.5 Europe Radiopharmaceutical for Nuclear Medicine Market Size Growth (2021-2026)
4.6 Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Radiopharmaceutical for Nuclear Medicine Market Size by Country (2021-2026)
5.2 Americas Radiopharmaceutical for Nuclear Medicine Market Size by Type (2021-2026)
5.3 Americas Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Radiopharmaceutical for Nuclear Medicine Market Size by Region (2021-2026)
6.2 APAC Radiopharmaceutical for Nuclear Medicine Market Size by Type (2021-2026)
6.3 APAC Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Radiopharmaceutical for Nuclear Medicine Market Size by Country (2021-2026)
7.2 Europe Radiopharmaceutical for Nuclear Medicine Market Size by Type (2021-2026)
7.3 Europe Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Radiopharmaceutical for Nuclear Medicine by Region (2021-2026)
8.2 Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size by Type (2021-2026)
8.3 Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL RADIOPHARMACEUTICAL FOR NUCLEAR MEDICINE MARKET FORECAST
10.1 Global Radiopharmaceutical for Nuclear Medicine Forecast by Region (2027-2032)
10.1.1 Global Radiopharmaceutical for Nuclear Medicine Forecast by Region (2027-2032)
10.1.2 Americas Radiopharmaceutical for Nuclear Medicine Forecast
10.1.3 APAC Radiopharmaceutical for Nuclear Medicine Forecast
10.1.4 Europe Radiopharmaceutical for Nuclear Medicine Forecast
10.1.5 Middle East & Africa Radiopharmaceutical for Nuclear Medicine Forecast
10.2 Americas Radiopharmaceutical for Nuclear Medicine Forecast by Country (2027-2032)
10.2.1 United States Market Radiopharmaceutical for Nuclear Medicine Forecast
10.2.2 Canada Market Radiopharmaceutical for Nuclear Medicine Forecast
10.2.3 Mexico Market Radiopharmaceutical for Nuclear Medicine Forecast
10.2.4 Brazil Market Radiopharmaceutical for Nuclear Medicine Forecast
10.3 APAC Radiopharmaceutical for Nuclear Medicine Forecast by Region (2027-2032)
10.3.1 China Radiopharmaceutical for Nuclear Medicine Market Forecast
10.3.2 Japan Market Radiopharmaceutical for Nuclear Medicine Forecast
10.3.3 Korea Market Radiopharmaceutical for Nuclear Medicine Forecast
10.3.4 Southeast Asia Market Radiopharmaceutical for Nuclear Medicine Forecast
10.3.5 India Market Radiopharmaceutical for Nuclear Medicine Forecast
10.3.6 Australia Market Radiopharmaceutical for Nuclear Medicine Forecast
10.4 Europe Radiopharmaceutical for Nuclear Medicine Forecast by Country (2027-2032)
10.4.1 Germany Market Radiopharmaceutical for Nuclear Medicine Forecast
10.4.2 France Market Radiopharmaceutical for Nuclear Medicine Forecast
10.4.3 UK Market Radiopharmaceutical for Nuclear Medicine Forecast
10.4.4 Italy Market Radiopharmaceutical for Nuclear Medicine Forecast
10.4.5 Russia Market Radiopharmaceutical for Nuclear Medicine Forecast
10.5 Middle East & Africa Radiopharmaceutical for Nuclear Medicine Forecast by Region (2027-2032)
10.5.1 Egypt Market Radiopharmaceutical for Nuclear Medicine Forecast
10.5.2 South Africa Market Radiopharmaceutical for Nuclear Medicine Forecast
10.5.3 Israel Market Radiopharmaceutical for Nuclear Medicine Forecast
10.5.4 Turkey Market Radiopharmaceutical for Nuclear Medicine Forecast
10.6 Global Radiopharmaceutical for Nuclear Medicine Forecast by Type (2027-2032)
10.7 Global Radiopharmaceutical for Nuclear Medicine Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Radiopharmaceutical for Nuclear Medicine Forecast
11 KEY PLAYERS ANALYSIS
11.1 Cardinal Health
11.1.1 Cardinal Health Company Information
11.1.2 Cardinal Health Radiopharmaceutical for Nuclear Medicine Product Offered
11.1.3 Cardinal Health Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Cardinal Health Main Business Overview
11.1.5 Cardinal Health Latest Developments
11.2 GE Healthcare
11.2.1 GE Healthcare Company Information
11.2.2 GE Healthcare Radiopharmaceutical for Nuclear Medicine Product Offered
11.2.3 GE Healthcare Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 GE Healthcare Main Business Overview
11.2.5 GE Healthcare Latest Developments
11.3 Lantheus Medical Imaging
11.3.1 Lantheus Medical Imaging Company Information
11.3.2 Lantheus Medical Imaging Radiopharmaceutical for Nuclear Medicine Product Offered
11.3.3 Lantheus Medical Imaging Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Lantheus Medical Imaging Main Business Overview
11.3.5 Lantheus Medical Imaging Latest Developments
11.4 Bayer
11.4.1 Bayer Company Information
11.4.2 Bayer Radiopharmaceutical for Nuclear Medicine Product Offered
11.4.3 Bayer Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Bayer Main Business Overview
11.4.5 Bayer Latest Developments
11.5 Eli Lilly
11.5.1 Eli Lilly Company Information
11.5.2 Eli Lilly Radiopharmaceutical for Nuclear Medicine Product Offered
11.5.3 Eli Lilly Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Eli Lilly Main Business Overview
11.5.5 Eli Lilly Latest Developments
11.6 Bracco Imaging
11.6.1 Bracco Imaging Company Information
11.6.2 Bracco Imaging Radiopharmaceutical for Nuclear Medicine Product Offered
11.6.3 Bracco Imaging Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Bracco Imaging Main Business Overview
11.6.5 Bracco Imaging Latest Developments
11.7 Curium Pharma
11.7.1 Curium Pharma Company Information
11.7.2 Curium Pharma Radiopharmaceutical for Nuclear Medicine Product Offered
11.7.3 Curium Pharma Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Curium Pharma Main Business Overview
11.7.5 Curium Pharma Latest Developments
11.8 Jubilant Pharmova
11.8.1 Jubilant Pharmova Company Information
11.8.2 Jubilant Pharmova Radiopharmaceutical for Nuclear Medicine Product Offered
11.8.3 Jubilant Pharmova Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Jubilant Pharmova Main Business Overview
11.8.5 Jubilant Pharmova Latest Developments
11.9 Aurobindo Pharma
11.9.1 Aurobindo Pharma Company Information
11.9.2 Aurobindo Pharma Radiopharmaceutical for Nuclear Medicine Product Offered
11.9.3 Aurobindo Pharma Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Aurobindo Pharma Main Business Overview
11.9.5 Aurobindo Pharma Latest Developments
11.10 Novartis
11.10.1 Novartis Company Information
11.10.2 Novartis Radiopharmaceutical for Nuclear Medicine Product Offered
11.10.3 Novartis Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Novartis Main Business Overview
11.10.5 Novartis Latest Developments
11.11 Siemens
11.11.1 Siemens Company Information
11.11.2 Siemens Radiopharmaceutical for Nuclear Medicine Product Offered
11.11.3 Siemens Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Siemens Main Business Overview
11.11.5 Siemens Latest Developments
11.12 NTP Radioisotopes
11.12.1 NTP Radioisotopes Company Information
11.12.2 NTP Radioisotopes Radiopharmaceutical for Nuclear Medicine Product Offered
11.12.3 NTP Radioisotopes Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 NTP Radioisotopes Main Business Overview
11.12.5 NTP Radioisotopes Latest Developments
11.13 ANSTO
11.13.1 ANSTO Company Information
11.13.2 ANSTO Radiopharmaceutical for Nuclear Medicine Product Offered
11.13.3 ANSTO Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 ANSTO Main Business Overview
11.13.5 ANSTO Latest Developments
11.14 Polatom
11.14.1 Polatom Company Information
11.14.2 Polatom Radiopharmaceutical for Nuclear Medicine Product Offered
11.14.3 Polatom Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Polatom Main Business Overview
11.14.5 Polatom Latest Developments
11.15 China Isotope & Radiation
11.15.1 China Isotope & Radiation Company Information
11.15.2 China Isotope & Radiation Radiopharmaceutical for Nuclear Medicine Product Offered
11.15.3 China Isotope & Radiation Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 China Isotope & Radiation Main Business Overview
11.15.5 China Isotope & Radiation Latest Developments
11.16 Yantai Dongcheng
11.16.1 Yantai Dongcheng Company Information
11.16.2 Yantai Dongcheng Radiopharmaceutical for Nuclear Medicine Product Offered
11.16.3 Yantai Dongcheng Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Yantai Dongcheng Main Business Overview
11.16.5 Yantai Dongcheng Latest Developments
11.17 Seed Biological Pharmacy
11.17.1 Seed Biological Pharmacy Company Information
11.17.2 Seed Biological Pharmacy Radiopharmaceutical for Nuclear Medicine Product Offered
11.17.3 Seed Biological Pharmacy Radiopharmaceutical for Nuclear Medicine Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Seed Biological Pharmacy Main Business Overview
11.17.5 Seed Biological Pharmacy Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Radiopharmaceutical for Nuclear Medicine Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Radiopharmaceutical for Nuclear Medicine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Diagnosis Nuclear Medicine
Table 4. Major Players of Therapeutic Nuclear Medicine
Table 5. Radiopharmaceutical for Nuclear Medicine Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Radiopharmaceutical for Nuclear Medicine Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Type (2021-2026)
Table 8. Major Players of Technetium-99m
Table 9. Major Players of Fluorine-18
Table 10. Major Players of Iodine-123
Table 11. Major Players of Iodine-131
Table 12. Major Players of Lutetium-177
Table 13. Major Players of Other
Table 14. Radiopharmaceutical for Nuclear Medicine Market Size CAGR by Disease (2021 VS 2025 VS 2032) & ($ millions)
Table 15. Global Radiopharmaceutical for Nuclear Medicine Market Size by Disease (2021-2026) & ($ millions)
Table 16. Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Disease (2021-2026)
Table 17. Major Players of Oncology
Table 18. Major Players of Cardiology
Table 19. Major Players of Other
Table 20. Radiopharmaceutical for Nuclear Medicine Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2026) & ($ millions)
Table 22. Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Application (2021-2026)
Table 23. Global Radiopharmaceutical for Nuclear Medicine Revenue by Player (2021-2026) & ($ millions)
Table 24. Global Radiopharmaceutical for Nuclear Medicine Revenue Market Share by Player (2021-2026)
Table 25. Radiopharmaceutical for Nuclear Medicine Key Players Head office and Products Offered
Table 26. Radiopharmaceutical for Nuclear Medicine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global Radiopharmaceutical for Nuclear Medicine Market Size by Region (2021-2026) & ($ millions)
Table 30. Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Region (2021-2026)
Table 31. Global Radiopharmaceutical for Nuclear Medicine Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Radiopharmaceutical for Nuclear Medicine Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Radiopharmaceutical for Nuclear Medicine Market Size by Country (2021-2026) & ($ millions)
Table 34. Americas Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Country (2021-2026)
Table 35. Americas Radiopharmaceutical for Nuclear Medicine Market Size by Type (2021-2026) & ($ millions)
Table 36. Americas Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Type (2021-2026)
Table 37. Americas Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2026) & ($ millions)
Table 38. Americas Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Application (2021-2026)
Table 39. APAC Radiopharmaceutical for Nuclear Medicine Market Size by Region (2021-2026) & ($ millions)
Table 40. APAC Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Region (2021-2026)
Table 41. APAC Radiopharmaceutical for Nuclear Medicine Market Size by Type (2021-2026) & ($ millions)
Table 42. APAC Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2026) & ($ millions)
Table 43. Europe Radiopharmaceutical for Nuclear Medicine Market Size by Country (2021-2026) & ($ millions)
Table 44. Europe Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Country (2021-2026)
Table 45. Europe Radiopharmaceutical for Nuclear Medicine Market Size by Type (2021-2026) & ($ millions)
Table 46. Europe Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2026) & ($ millions)
Table 47. Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size by Region (2021-2026) & ($ millions)
Table 48. Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size by Type (2021-2026) & ($ millions)
Table 49. Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2026) & ($ millions)
Table 50. Key Market Drivers & Growth Opportunities of Radiopharmaceutical for Nuclear Medicine
Table 51. Key Market Challenges & Risks of Radiopharmaceutical for Nuclear Medicine
Table 52. Key Industry Trends of Radiopharmaceutical for Nuclear Medicine
Table 53. Global Radiopharmaceutical for Nuclear Medicine Market Size Forecast by Region (2027-2032) & ($ millions)
Table 54. Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share Forecast by Region (2027-2032)
Table 55. Global Radiopharmaceutical for Nuclear Medicine Market Size Forecast by Type (2027-2032) & ($ millions)
Table 56. Global Radiopharmaceutical for Nuclear Medicine Market Size Forecast by Application (2027-2032) & ($ millions)
Table 57. Cardinal Health Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 58. Cardinal Health Radiopharmaceutical for Nuclear Medicine Product Offered
Table 59. Cardinal Health Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 60. Cardinal Health Main Business
Table 61. Cardinal Health Latest Developments
Table 62. GE Healthcare Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 63. GE Healthcare Radiopharmaceutical for Nuclear Medicine Product Offered
Table 64. GE Healthcare Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. GE Healthcare Main Business
Table 66. GE Healthcare Latest Developments
Table 67. Lantheus Medical Imaging Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 68. Lantheus Medical Imaging Radiopharmaceutical for Nuclear Medicine Product Offered
Table 69. Lantheus Medical Imaging Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. Lantheus Medical Imaging Main Business
Table 71. Lantheus Medical Imaging Latest Developments
Table 72. Bayer Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 73. Bayer Radiopharmaceutical for Nuclear Medicine Product Offered
Table 74. Bayer Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Bayer Main Business
Table 76. Bayer Latest Developments
Table 77. Eli Lilly Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 78. Eli Lilly Radiopharmaceutical for Nuclear Medicine Product Offered
Table 79. Eli Lilly Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. Eli Lilly Main Business
Table 81. Eli Lilly Latest Developments
Table 82. Bracco Imaging Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 83. Bracco Imaging Radiopharmaceutical for Nuclear Medicine Product Offered
Table 84. Bracco Imaging Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Bracco Imaging Main Business
Table 86. Bracco Imaging Latest Developments
Table 87. Curium Pharma Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 88. Curium Pharma Radiopharmaceutical for Nuclear Medicine Product Offered
Table 89. Curium Pharma Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. Curium Pharma Main Business
Table 91. Curium Pharma Latest Developments
Table 92. Jubilant Pharmova Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 93. Jubilant Pharmova Radiopharmaceutical for Nuclear Medicine Product Offered
Table 94. Jubilant Pharmova Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Jubilant Pharmova Main Business
Table 96. Jubilant Pharmova Latest Developments
Table 97. Aurobindo Pharma Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 98. Aurobindo Pharma Radiopharmaceutical for Nuclear Medicine Product Offered
Table 99. Aurobindo Pharma Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 100. Aurobindo Pharma Main Business
Table 101. Aurobindo Pharma Latest Developments
Table 102. Novartis Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 103. Novartis Radiopharmaceutical for Nuclear Medicine Product Offered
Table 104. Novartis Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 105. Novartis Main Business
Table 106. Novartis Latest Developments
Table 107. Siemens Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 108. Siemens Radiopharmaceutical for Nuclear Medicine Product Offered
Table 109. Siemens Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 110. Siemens Main Business
Table 111. Siemens Latest Developments
Table 112. NTP Radioisotopes Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 113. NTP Radioisotopes Radiopharmaceutical for Nuclear Medicine Product Offered
Table 114. NTP Radioisotopes Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 115. NTP Radioisotopes Main Business
Table 116. NTP Radioisotopes Latest Developments
Table 117. ANSTO Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 118. ANSTO Radiopharmaceutical for Nuclear Medicine Product Offered
Table 119. ANSTO Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 120. ANSTO Main Business
Table 121. ANSTO Latest Developments
Table 122. Polatom Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 123. Polatom Radiopharmaceutical for Nuclear Medicine Product Offered
Table 124. Polatom Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 125. Polatom Main Business
Table 126. Polatom Latest Developments
Table 127. China Isotope & Radiation Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 128. China Isotope & Radiation Radiopharmaceutical for Nuclear Medicine Product Offered
Table 129. China Isotope & Radiation Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 130. China Isotope & Radiation Main Business
Table 131. China Isotope & Radiation Latest Developments
Table 132. Yantai Dongcheng Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 133. Yantai Dongcheng Radiopharmaceutical for Nuclear Medicine Product Offered
Table 134. Yantai Dongcheng Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 135. Yantai Dongcheng Main Business
Table 136. Yantai Dongcheng Latest Developments
Table 137. Seed Biological Pharmacy Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 138. Seed Biological Pharmacy Radiopharmaceutical for Nuclear Medicine Product Offered
Table 139. Seed Biological Pharmacy Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 140. Seed Biological Pharmacy Main Business
Table 141. Seed Biological Pharmacy Latest Developments
Table 1. Radiopharmaceutical for Nuclear Medicine Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Radiopharmaceutical for Nuclear Medicine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Diagnosis Nuclear Medicine
Table 4. Major Players of Therapeutic Nuclear Medicine
Table 5. Radiopharmaceutical for Nuclear Medicine Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Radiopharmaceutical for Nuclear Medicine Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Type (2021-2026)
Table 8. Major Players of Technetium-99m
Table 9. Major Players of Fluorine-18
Table 10. Major Players of Iodine-123
Table 11. Major Players of Iodine-131
Table 12. Major Players of Lutetium-177
Table 13. Major Players of Other
Table 14. Radiopharmaceutical for Nuclear Medicine Market Size CAGR by Disease (2021 VS 2025 VS 2032) & ($ millions)
Table 15. Global Radiopharmaceutical for Nuclear Medicine Market Size by Disease (2021-2026) & ($ millions)
Table 16. Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Disease (2021-2026)
Table 17. Major Players of Oncology
Table 18. Major Players of Cardiology
Table 19. Major Players of Other
Table 20. Radiopharmaceutical for Nuclear Medicine Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2026) & ($ millions)
Table 22. Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Application (2021-2026)
Table 23. Global Radiopharmaceutical for Nuclear Medicine Revenue by Player (2021-2026) & ($ millions)
Table 24. Global Radiopharmaceutical for Nuclear Medicine Revenue Market Share by Player (2021-2026)
Table 25. Radiopharmaceutical for Nuclear Medicine Key Players Head office and Products Offered
Table 26. Radiopharmaceutical for Nuclear Medicine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global Radiopharmaceutical for Nuclear Medicine Market Size by Region (2021-2026) & ($ millions)
Table 30. Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Region (2021-2026)
Table 31. Global Radiopharmaceutical for Nuclear Medicine Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Radiopharmaceutical for Nuclear Medicine Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Radiopharmaceutical for Nuclear Medicine Market Size by Country (2021-2026) & ($ millions)
Table 34. Americas Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Country (2021-2026)
Table 35. Americas Radiopharmaceutical for Nuclear Medicine Market Size by Type (2021-2026) & ($ millions)
Table 36. Americas Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Type (2021-2026)
Table 37. Americas Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2026) & ($ millions)
Table 38. Americas Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Application (2021-2026)
Table 39. APAC Radiopharmaceutical for Nuclear Medicine Market Size by Region (2021-2026) & ($ millions)
Table 40. APAC Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Region (2021-2026)
Table 41. APAC Radiopharmaceutical for Nuclear Medicine Market Size by Type (2021-2026) & ($ millions)
Table 42. APAC Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2026) & ($ millions)
Table 43. Europe Radiopharmaceutical for Nuclear Medicine Market Size by Country (2021-2026) & ($ millions)
Table 44. Europe Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Country (2021-2026)
Table 45. Europe Radiopharmaceutical for Nuclear Medicine Market Size by Type (2021-2026) & ($ millions)
Table 46. Europe Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2026) & ($ millions)
Table 47. Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size by Region (2021-2026) & ($ millions)
Table 48. Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size by Type (2021-2026) & ($ millions)
Table 49. Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2026) & ($ millions)
Table 50. Key Market Drivers & Growth Opportunities of Radiopharmaceutical for Nuclear Medicine
Table 51. Key Market Challenges & Risks of Radiopharmaceutical for Nuclear Medicine
Table 52. Key Industry Trends of Radiopharmaceutical for Nuclear Medicine
Table 53. Global Radiopharmaceutical for Nuclear Medicine Market Size Forecast by Region (2027-2032) & ($ millions)
Table 54. Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share Forecast by Region (2027-2032)
Table 55. Global Radiopharmaceutical for Nuclear Medicine Market Size Forecast by Type (2027-2032) & ($ millions)
Table 56. Global Radiopharmaceutical for Nuclear Medicine Market Size Forecast by Application (2027-2032) & ($ millions)
Table 57. Cardinal Health Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 58. Cardinal Health Radiopharmaceutical for Nuclear Medicine Product Offered
Table 59. Cardinal Health Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 60. Cardinal Health Main Business
Table 61. Cardinal Health Latest Developments
Table 62. GE Healthcare Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 63. GE Healthcare Radiopharmaceutical for Nuclear Medicine Product Offered
Table 64. GE Healthcare Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. GE Healthcare Main Business
Table 66. GE Healthcare Latest Developments
Table 67. Lantheus Medical Imaging Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 68. Lantheus Medical Imaging Radiopharmaceutical for Nuclear Medicine Product Offered
Table 69. Lantheus Medical Imaging Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. Lantheus Medical Imaging Main Business
Table 71. Lantheus Medical Imaging Latest Developments
Table 72. Bayer Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 73. Bayer Radiopharmaceutical for Nuclear Medicine Product Offered
Table 74. Bayer Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Bayer Main Business
Table 76. Bayer Latest Developments
Table 77. Eli Lilly Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 78. Eli Lilly Radiopharmaceutical for Nuclear Medicine Product Offered
Table 79. Eli Lilly Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. Eli Lilly Main Business
Table 81. Eli Lilly Latest Developments
Table 82. Bracco Imaging Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 83. Bracco Imaging Radiopharmaceutical for Nuclear Medicine Product Offered
Table 84. Bracco Imaging Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Bracco Imaging Main Business
Table 86. Bracco Imaging Latest Developments
Table 87. Curium Pharma Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 88. Curium Pharma Radiopharmaceutical for Nuclear Medicine Product Offered
Table 89. Curium Pharma Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. Curium Pharma Main Business
Table 91. Curium Pharma Latest Developments
Table 92. Jubilant Pharmova Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 93. Jubilant Pharmova Radiopharmaceutical for Nuclear Medicine Product Offered
Table 94. Jubilant Pharmova Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Jubilant Pharmova Main Business
Table 96. Jubilant Pharmova Latest Developments
Table 97. Aurobindo Pharma Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 98. Aurobindo Pharma Radiopharmaceutical for Nuclear Medicine Product Offered
Table 99. Aurobindo Pharma Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 100. Aurobindo Pharma Main Business
Table 101. Aurobindo Pharma Latest Developments
Table 102. Novartis Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 103. Novartis Radiopharmaceutical for Nuclear Medicine Product Offered
Table 104. Novartis Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 105. Novartis Main Business
Table 106. Novartis Latest Developments
Table 107. Siemens Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 108. Siemens Radiopharmaceutical for Nuclear Medicine Product Offered
Table 109. Siemens Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 110. Siemens Main Business
Table 111. Siemens Latest Developments
Table 112. NTP Radioisotopes Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 113. NTP Radioisotopes Radiopharmaceutical for Nuclear Medicine Product Offered
Table 114. NTP Radioisotopes Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 115. NTP Radioisotopes Main Business
Table 116. NTP Radioisotopes Latest Developments
Table 117. ANSTO Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 118. ANSTO Radiopharmaceutical for Nuclear Medicine Product Offered
Table 119. ANSTO Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 120. ANSTO Main Business
Table 121. ANSTO Latest Developments
Table 122. Polatom Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 123. Polatom Radiopharmaceutical for Nuclear Medicine Product Offered
Table 124. Polatom Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 125. Polatom Main Business
Table 126. Polatom Latest Developments
Table 127. China Isotope & Radiation Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 128. China Isotope & Radiation Radiopharmaceutical for Nuclear Medicine Product Offered
Table 129. China Isotope & Radiation Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 130. China Isotope & Radiation Main Business
Table 131. China Isotope & Radiation Latest Developments
Table 132. Yantai Dongcheng Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 133. Yantai Dongcheng Radiopharmaceutical for Nuclear Medicine Product Offered
Table 134. Yantai Dongcheng Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 135. Yantai Dongcheng Main Business
Table 136. Yantai Dongcheng Latest Developments
Table 137. Seed Biological Pharmacy Details, Company Type, Radiopharmaceutical for Nuclear Medicine Area Served and Its Competitors
Table 138. Seed Biological Pharmacy Radiopharmaceutical for Nuclear Medicine Product Offered
Table 139. Seed Biological Pharmacy Radiopharmaceutical for Nuclear Medicine Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 140. Seed Biological Pharmacy Main Business
Table 141. Seed Biological Pharmacy Latest Developments
LIST OF FIGURES
Figure 1. Radiopharmaceutical for Nuclear Medicine Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Radiopharmaceutical for Nuclear Medicine Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Radiopharmaceutical for Nuclear Medicine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Radiopharmaceutical for Nuclear Medicine Sales Market Share by Country/Region (2025)
Figure 8. Radiopharmaceutical for Nuclear Medicine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Type in 2025
Figure 10. Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Disease in 2025
Figure 11. Radiopharmaceutical for Nuclear Medicine in Hospital
Figure 12. Global Radiopharmaceutical for Nuclear Medicine Market: Hospital (2021-2026) & ($ millions)
Figure 13. Radiopharmaceutical for Nuclear Medicine in Imaging Center
Figure 14. Global Radiopharmaceutical for Nuclear Medicine Market: Imaging Center (2021-2026) & ($ millions)
Figure 15. Radiopharmaceutical for Nuclear Medicine in Others
Figure 16. Global Radiopharmaceutical for Nuclear Medicine Market: Others (2021-2026) & ($ millions)
Figure 17. Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Application in 2025
Figure 18. Global Radiopharmaceutical for Nuclear Medicine Revenue Market Share by Player in 2025
Figure 19. Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Region (2021-2026)
Figure 20. Americas Radiopharmaceutical for Nuclear Medicine Market Size 2021-2026 ($ millions)
Figure 21. APAC Radiopharmaceutical for Nuclear Medicine Market Size 2021-2026 ($ millions)
Figure 22. Europe Radiopharmaceutical for Nuclear Medicine Market Size 2021-2026 ($ millions)
Figure 23. Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size 2021-2026 ($ millions)
Figure 24. Americas Radiopharmaceutical for Nuclear Medicine Value Market Share by Country in 2025
Figure 25. United States Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 26. Canada Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 27. Mexico Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 28. Brazil Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 29. APAC Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Region in 2025
Figure 30. APAC Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Type (2021-2026)
Figure 31. APAC Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Application (2021-2026)
Figure 32. China Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 33. Japan Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 34. South Korea Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 35. Southeast Asia Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 36. India Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 37. Australia Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 38. Europe Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Country in 2025
Figure 39. Europe Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Type (2021-2026)
Figure 40. Europe Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Application (2021-2026)
Figure 41. Germany Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 42. France Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 43. UK Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 44. Italy Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 45. Russia Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 46. Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Region (2021-2026)
Figure 47. Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Type (2021-2026)
Figure 48. Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Application (2021-2026)
Figure 49. Egypt Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 50. South Africa Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 51. Israel Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 52. Turkey Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 53. GCC Countries Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 54. Americas Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 55. APAC Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 56. Europe Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 57. Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 58. United States Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 59. Canada Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 60. Mexico Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 61. Brazil Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 62. China Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 63. Japan Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 64. Korea Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 65. Southeast Asia Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 66. India Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 67. Australia Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 68. Germany Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 69. France Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 70. UK Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 71. Italy Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 72. Russia Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 73. Egypt Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 74. South Africa Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 75. Israel Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 76. Turkey Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 77. Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share Forecast by Type (2027-2032)
Figure 78. Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share Forecast by Application (2027-2032)
Figure 79. GCC Countries Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 1. Radiopharmaceutical for Nuclear Medicine Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Radiopharmaceutical for Nuclear Medicine Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Radiopharmaceutical for Nuclear Medicine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Radiopharmaceutical for Nuclear Medicine Sales Market Share by Country/Region (2025)
Figure 8. Radiopharmaceutical for Nuclear Medicine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Type in 2025
Figure 10. Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Disease in 2025
Figure 11. Radiopharmaceutical for Nuclear Medicine in Hospital
Figure 12. Global Radiopharmaceutical for Nuclear Medicine Market: Hospital (2021-2026) & ($ millions)
Figure 13. Radiopharmaceutical for Nuclear Medicine in Imaging Center
Figure 14. Global Radiopharmaceutical for Nuclear Medicine Market: Imaging Center (2021-2026) & ($ millions)
Figure 15. Radiopharmaceutical for Nuclear Medicine in Others
Figure 16. Global Radiopharmaceutical for Nuclear Medicine Market: Others (2021-2026) & ($ millions)
Figure 17. Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Application in 2025
Figure 18. Global Radiopharmaceutical for Nuclear Medicine Revenue Market Share by Player in 2025
Figure 19. Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Region (2021-2026)
Figure 20. Americas Radiopharmaceutical for Nuclear Medicine Market Size 2021-2026 ($ millions)
Figure 21. APAC Radiopharmaceutical for Nuclear Medicine Market Size 2021-2026 ($ millions)
Figure 22. Europe Radiopharmaceutical for Nuclear Medicine Market Size 2021-2026 ($ millions)
Figure 23. Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size 2021-2026 ($ millions)
Figure 24. Americas Radiopharmaceutical for Nuclear Medicine Value Market Share by Country in 2025
Figure 25. United States Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 26. Canada Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 27. Mexico Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 28. Brazil Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 29. APAC Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Region in 2025
Figure 30. APAC Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Type (2021-2026)
Figure 31. APAC Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Application (2021-2026)
Figure 32. China Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 33. Japan Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 34. South Korea Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 35. Southeast Asia Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 36. India Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 37. Australia Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 38. Europe Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Country in 2025
Figure 39. Europe Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Type (2021-2026)
Figure 40. Europe Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Application (2021-2026)
Figure 41. Germany Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 42. France Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 43. UK Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 44. Italy Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 45. Russia Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 46. Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Region (2021-2026)
Figure 47. Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Type (2021-2026)
Figure 48. Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size Market Share by Application (2021-2026)
Figure 49. Egypt Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 50. South Africa Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 51. Israel Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 52. Turkey Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 53. GCC Countries Radiopharmaceutical for Nuclear Medicine Market Size Growth 2021-2026 ($ millions)
Figure 54. Americas Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 55. APAC Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 56. Europe Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 57. Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 58. United States Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 59. Canada Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 60. Mexico Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 61. Brazil Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 62. China Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 63. Japan Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 64. Korea Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 65. Southeast Asia Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 66. India Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 67. Australia Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 68. Germany Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 69. France Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 70. UK Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 71. Italy Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 72. Russia Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 73. Egypt Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 74. South Africa Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 75. Israel Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 76. Turkey Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
Figure 77. Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share Forecast by Type (2027-2032)
Figure 78. Global Radiopharmaceutical for Nuclear Medicine Market Size Market Share Forecast by Application (2027-2032)
Figure 79. GCC Countries Radiopharmaceutical for Nuclear Medicine Market Size 2027-2032 ($ millions)
